Latest News & Updates
Breaking News
3 hours ago
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Other trending news you may like to read
92 US Biosimilar Approvals Reshape Manufacturer Strategy in 2026
Samsung Bioepis Q2 2026 report records 92 US biosimilar approvals, signaling tighter interchangeability and QA demands for manufacturers.
Pharma Now Editorial Team
Lilly's $2.3B Ajax Bet Reshapes JAK2 Inhibitor Pipeline
Lilly acquires Ajax Therapeutics for up to $2.3B, adding a Phase 1 Type II JAK2 inhibitor targeting rare blood cancers to its pipeline.
Pharma Now Editorial Team
FDA Oncology Wave Q1 2026: Eight Approvals Reshape Manufacturing Readiness
Eight FDA oncology approvals in Q1 2026 demand immediate manufacturing, labeling, and combination product readiness across QA and regulatory functions.
Pharma Now Editorial Team
AstraZeneca Faces Dual ODAC Scrutiny on Biomarker-Gated Oncology NDAs
AstraZeneca's camizestrant and capivasertib face ODAC review April 30, setting a precedent for biomarker-gated oncology approvals.
Pharma Now Editorial Team
